Trial Profile
A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects With Hematologic Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; T-cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors AbbVie
- 09 Aug 2023 Planned End Date changed from 30 Sep 2023 to 2 Mar 2024.
- 09 Aug 2023 Planned primary completion date changed from 30 Sep 2023 to 2 Mar 2024.
- 04 Jan 2023 Planned End Date changed from 30 Oct 2022 to 30 Sep 2023.